Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice